A detailed history of Gamble Jones Investment Counsel transactions in Alaunos Therapeutics, Inc. stock. As of the latest transaction made, Gamble Jones Investment Counsel holds 61,000 shares of TCRT stock, worth $129,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,000
Previous 61,000 -0.0%
Holding current value
$129,320
Previous $105,000 62.86%
% of portfolio
0.0%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022

BUY
$1.09 - $1.89 $32,700 - $56,700
30,000 Added 96.77%
61,000 $66,000
Q2 2020

Aug 19, 2020

BUY
$2.2 - $3.71 $2,200 - $3,710
1,000 Added 3.33%
31,000 $102,000
Q1 2020

May 08, 2020

BUY
$1.9 - $4.98 $3,800 - $9,960
2,000 Added 7.14%
30,000 $74,000
Q2 2019

Aug 20, 2019

SELL
$3.98 - $6.2 $7,960 - $12,400
-2,000 Reduced 6.67%
28,000 $163,000
Q4 2018

Feb 04, 2019

BUY
$1.61 - $3.62 $48,300 - $108,600
30,000 New
30,000 $56,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Gamble Jones Investment Counsel Portfolio

Follow Gamble Jones Investment Counsel and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamble Jones Investment Counsel, based on Form 13F filings with the SEC.

News

Stay updated on Gamble Jones Investment Counsel with notifications on news.